This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA.
- Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events
- Secondary Factors affecting safety and to confirm the efficacy such as DAS28.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01145352?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
